Neoadjuvant Therapy in Cervical Cancer
Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Aug 14, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment approach for women with locally advanced cervical cancer, specifically those with stage IB3 and IIA2 cervical cancer that tests positive for a protein called HER2. The trial aims to explore the effectiveness of a combination of two medications: Disitamab Vedotin and Cisplatin. The goal is to see if this new combination can improve the chances of patients having a complete response to treatment before surgery, as well as to reduce complications during surgery and improve overall survival rates.
To be eligible for this trial, participants must have a diagnosis of cervical squamous cell carcinoma and be HER2 positive. Unfortunately, women with a different type of cervical cancer called adenocarcinoma cannot participate. If you or someone you know is considering joining this study, it’s important to understand that the trial is currently recruiting participants, and it offers a chance to explore a potentially better treatment option that could lead to improved outcomes.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of cervical squamous cell carcinoma
- • HER-2 positive
- Exclusion Criteria:
- • Cervical adenocarcinoma
About Qilu Hospital Of Shandong University
Qilu Hospital of Shandong University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. Affiliated with Shandong University, the hospital integrates clinical practice with education and research, fostering an environment that promotes scientific discovery and the development of new therapies. With a commitment to high standards of clinical excellence and ethical research practices, Qilu Hospital plays a pivotal role in enhancing patient outcomes and contributing to the global medical community through a diverse range of clinical trials and studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
Jinan, , China
Patients applied
Trial Officials
Kun Song
Principal Investigator
Qilu Hospital of Shandong University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported